You just read:

Second Genome Doses First Patient In Phase 2 Clinical Study Of SGM-1019 For The Treatment Of Nonalcoholic Steatohepatitis (NASH)

News provided by

Second Genome, Inc.

Jan 23, 2019, 08:00 ET